Ufuk MEMİŞ, ERDEM KARADENİZ, Müfide Nuran AKÇAY, Nurinnisa ÖZTÜRK

Determination of galectin-3, hepsin (Tmprss 1) and thyroid transcription factor-1 levels in thyroid cancer patients: A prospective case-control study

Aim: This study aimed to the efficiacy of usage galectin-3, hepsin, and thyroid transcription factor-1 (TTF-1) levels as markers for the differentiation between patients with malignant and benign thyroid nodules. Methods: The study was done prospectively between January 2018 and April 2018 in our clinic, in patients who were diagnosed with thyroid nodules and scheduled for surgery. Galectin-3, hepsin, and TTF-1 levels were measured in the preoperative serum of the benign and malignant groups. The measured levels were evaluated statistically to determine whether there was any significant difference between the malignant and benign groups. Results: When the levels of galectin-3, hepsin, and TTF-1 in the malignant and benign groups were compared, there was a statistically significant difference in TTF-1 levels (p=0.038). However, no significant difference was found in hepsin and galectin-3. When the macropapillary and micropapillary types were compared within the malignant patient group, there was a significant difference between the galectin-3 levels (p = 0.009), but no difference was found between hepsin and TTF-1. Conclusions: It was seen that the decrease of galectin-3 levels in thyroid papillary carcinoma could be effective in the transformation from microcarcinoma to macrocarcinoma, and TTF-1 could be an important marker for the differentiation between benign and malignant thyroid nodules.

Tiroit kanserli hastalarda galektin-3, hepsin (Tmprss1) ve tiroit transkripsiyon faktör-1 seviyelerinin belirlenmesi: Bir prospektif vaka-kontrol çalışması

Amaç: Çalışmada; galektin-3, hepsin ve tiroit transkripsiyon faktör-1 (TTF-1)’in kan değerlerinin tiroit nodüllerinde malign ve benign ayrımındaki tanısal değerini araştırmayı amaçladık. Yöntemler: Çalışma kliniğimizde Ocak 2018 ile Nisan 2018 tarihleri arasında tiroit nodülü nedeniyle operasyon planlanan hastalarda prospektif olarak yürütüldü. Benign ve malign grupların ameliyat öncesi elde edilen serumlarında galektin-3, hepsin ve TTF-1 seviyeleri açısından farklılık olup olmadığı istatistiksel olarak araştırıldı. Bulgular: Malign ve benign grupta ölçülen galektin-3, hepsin ve TTF-1 seviyeleri karşılaştırıldığında; TTF-1 seviyelerinde istatistiksel olarak anlamlı fark bulunurken (p=0,038), hepsin ve galektin-3’te anlamlı fark tespit edilmedi. Malign hasta grubunda makropapiller ve mikropapiller tip karşılaştırıldığında galektin-3 seviyeleri arasından anlamlı bir fark tespit edilirken (p=0,009), hepsin ve TTF-1 arasında fark tespit edilmedi. Sonuç: Tiroid papiller karsinomunda galectin-3 seviyesinin düşmesinin mikro karsinomdan makro karsinoma dönüşümde etkili olabileceği, TTF-1’ in tiroid nodüllerinde benign ve malign ayrımında önemli bir belirteç olabileceği görüldü.

PDF

___

1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA otolaryngology-head & neck surgery. 2014;140:317-22.

2. Ogilvie JB, Piatigorsky EJ, Clark OH. Current status of fine needle aspiration for thyroid nodules. Adv Surg. 2006;40:223-38.

3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.

4. Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid. 2013;23:449-55.

5. Abd-El Raouf SM, Ibrahim TR. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Pathol Res Pract. 2014;210:971-8.

6. Zhang C, Zhang M, Song S. Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation. Cancer Lett. 2018;438:105-15.

7. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 2003;22:237-58.

8. Tan A, Etit D, Bayol U, Altinel D, Tan S. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol. 2011;15:108-16.

9. Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA, et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med. 2009;13:1977-86.

10. Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid. 1998;8:15-21.

11. de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012;7:97.

12. Wu G, Wang J, Zhou Z, Li T, Tang F. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity? J Int Med Res. 2013;41:975-83.

13. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol. 2000;31:428-33.

14. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol. 2004;171:187-91.

15. Xing P, Li JG, Jin F, Zhao TT, Liu Q, Dong HT, et al. Clinical and biological significance of hepsin overexpression in breast cancer. J Investig Med. 2011;59:803-10.

16. El-Rebey HS, Kandil MA, Samaka RM, Al-Sharaky DR, El Deeb K. The Role of Hepsin in Endometrial Carcinoma. Appl Immunohistochem Mol Morphol. 2017;25:624-631.

17. Tanimoto H, Yan Y, Clarke J, Korourian S, Shigemasa K, Parmley TH, et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 1997;57:2884-7.

18. Zhang M, Zhao J, Tang W, Wang Y, Peng P, Li L, et al. High Hepsin expression predicts poor prognosis in Gastric Cancer. Sci Rep. 2016;6:36902.

19. Kimura S. Thyroid-specific transcription factors and their roles in thyroid cancer. J Thyroid Res. 2011;2011:710213.

20. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009;27:271-8.

21. Zhang HM, Fan TT, Li W, Li XX. Expressions and significances of TTF-1 and PTEN in early endometrial cancer. Eur Rev Med Pharmacol Sci. 2017;21(3 Suppl):20-6.

22. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2008;21:192-200.

23. Fenton CL, Patel A, Burch HB, Tuttle RM, Francis GL. Nuclear localization of thyroid transcription factor-1 correlates with serum thyrotropin activity and may be increased in differentiated thyroid carcinomas with aggressive clinical course. Ann Clin Lab Sci. 2001;31:245-52.

24. Katoh R, Kawaoi A, Miyagi E, Li X, Suzuki K, Nakamura Y, et al. Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization. Mod Pathol. 2000;13:570-6.

25. Ai L, Yu Y, Liu X, Wang C, Shi J, Sun H, et al. Are the SNPs of NKX2-1 associated with papillary thyroid carcinoma in the Han population of Northern China? Front Med. 2014;8:113-7.